Biovica

Our DiviTum® TKa test is 510 (k)-cleared and CE-IVD for monitoring disease progression in cancer patients. First indication MBC, HR+ postmenopausal women.

[Biovica @Biovica]

We are excited about the strong DiviTum TKa results recently published in JCO Precision Oncology! 🎉

The study highlights the potential of longitudinal TKa monitoring in MBC and early BC to support treatment decisions.
Read more: https://t.co/g2GFYxplk6

#bscm #divitum @onclive

[Biovica @Biovica]

Register for our upcoming Q2 Earnings call taking place:
18th December, 2025 at 15:00 CET.

Register here: https://t.co/lUeXpswRF1

Presenters are:
Anders Rylander, CEO
Anders Morén, CFO

#biovicb #investors #oncology #biomarker #pharma

[Biovica @Biovica]

At #SABCS25?

Dec 10th, 5-6:30 PM CST, hear Dr. Mariya Rozenblit from Yale School of Medicine present.

Read the Abstract PS2-09-28: https://t.co/RCT5tFeU0s
The #biomarker here: https://t.co/kJ7kBL3ppx

#biomarker #personalizedmedicine #divitum #bscm @onclive

[Biovica @Biovica]

At #SABCS25?

Dec 10th, 5-6:30 PM CST, hear Dr. Elena Michaels from Mass General Brigham Cancer Institute present.

Read the Abstract PS2-10-21: https://t.co/RCT5tFeU0s
The #biomarker here: https://t.co/kJ7kBL3ppx

#biomarker #personalizedmedicine #divitum #bscm @onclive

[Biovica @Biovica]

We’re excited to introduce the team representing us at SABCS25!

They look forward to discussing our latest work with TKa—the breast cancer biomarker that measures cell proliferation.

Submit a request to meet: https://t.co/8iNHdGGpHA

#SABSC25 #biomarker #bscm @onclive

[Biovica @Biovica]

We are proud that our SVP Hanna Ritzén is presenting at the upcoming 18th EBF.

On Nov 18th, 2025: Join her at 11:10 AM local time.

Read more about our biomarker DiviTum TKa here: https://t.co/8geZ65Xa5l

#EBF2025 #bioanalysisforum #divitum #precesionmedicine #oncology

[Biovica @Biovica]

Remember to register!

Our upcoming Q1 Earnings call is taking place:
11th September, 2025 at 14:00 CET.

Register here: https://t.co/fAr15WYQx3

Presenters are:
Anders Rylander, CEO
Anders Morén, CFO

#biovicb #investors #oncology #biomarker #pharma

[Biovica @Biovica]

https://t.co/8yEnorFT1U
Start monitoring treatment response and tumor proliferation of your breast cancer patients today!

In the US?

Collect a small amount of blood and send it to Biovica in our pre-paid mailer. You will receive results in 2-4 days: https://t.co/D5TgH3VSEX

[Biovica @Biovica]

Register for our upcoming Q1 Earnings call taking place:
11th September, 2025 at 14:00 CET.

Register here: https://t.co/fAr15WYQx3

Presenters are:
Anders Rylander, CEO
Anders Morén, CFO

#biovicb #investors #oncology #biomarker #pharma

[Biovica @Biovica]

New Interview from RedEye!

How will Biovica use the proceeds?
Where does Biovica stand with the newly signed partner agreements?

Watch it on our website for investor relations.

Read more on RedEye.

#biovicb #investors #oncology #firstnorth

[Biovica @Biovica]

Today, we launch our DiviTum® Tka test for use in early breast cancer for patients in adjuvant therapy!

It is available as a laboratory-developed test (LDT) from our CLIA-certified laboratory in the US.

#Biovica #biomarker #bscm #divitum #precisionmedicine #breastcancer @onco

[Biovica @Biovica]

We have signed a new Pharma work order! 🎉
We are excited to receive yet another work order - the 4th contract from a leading Tier-1 pharma company. This time for 3 MSEK.

Read More here: https://t.co/R8U8JVZOdl

#biovica #personalizedmedicine #biomarker #firstnorth

[Biovica @Biovica]

Biovicas innovation ligger bokstavligen i blodet https://t.co/Rtx8EFw54j #lightweb via @lightweb

[Biovica @Biovica]

Biovicas vd: ”Förr tog det månader. Nu tar det ett blodprov” https://t.co/RdDgU5qaZd #lightweb via @lightweb

[Biovica @Biovica]

Biovica granted new European patent!

The patent will come into effect on July 16, 2025, in conjunction with its publication in the European Patent Bulletin.

Read More: https://t.co/tR6QuRmkaK

#pharma #biomarker #oncology #immunooncology #biovicb #immunecheckpointinhibitor

[Biovica @Biovica]

REMINDER!

Do not miss our Q4 Earnings call taking place:
18th June, 2025 at 15:00 CET.

To register https://t.co/1nbJfNP9uN

Presenters are:
Anders Rylander, CEO
Anders Morén, CFO

#biovicb #investors #oncology #biomarker #pharma

[Biovica @Biovica]

A milestone in our growing customer base: we have signed an agreement with a fifth Tier-1 US biopharma company! 📣📢🔊

Read More on https://t.co/z6l6SfYoyo

#biovica #personalizedmedicine #biomarker #firstnorth

[Biovica @Biovica]

Notice of extra general meeting in Biovica International AB!

Monday 14 July 2025, at 10:00 CET at Baker McKenzie Advokatbyrå on Vasagatan 7, 101 23 Stockholm.

To attend the general meeting, Click here: https://t.co/tR6QuRmkaK
#biovicb #investor #nasdaqfirstnorth

[Biovica @Biovica]

Biovica resolves on a rights issue of approximately SEK 80.1 million! 💵💶

The Board of Directors of Biovica has today approved by an EGM a new issue of A-shares and B-shares.

Read the details on https://t.co/OKXcseJGRV

#biovicb #investors #oncology #firstnorth

[Biovica @Biovica]

Biovica announces financial targets following key partnerships and commercial progress! 🎯💰💵💶🎗

Today, we have announced financial goals for the upcoming two fiscal years. Read the goals on https://t.co/OKXcseJGRV

#biovicb #investors #oncology #firstnorth